We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now


It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Anavex Life Sciences Corporation

Anavex Life Sciences Corporation (AVXL)

At close: March 01 04:00PM
( 4.67% )
After Hours: 05:39PM


StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade
1.003.706.300. %00-
1.502.655.800.004.2250.000.00 %00-
2.002.955.200.004.0750.000.00 %00-
2.502.454.400.003.4250.000.00 %00-
3.001.954.200.003.0750.000.00 %00-
3.501.403.700.002.550.000.00 %00-
4.000.953.101.502.0250.000.00 %00-
4.500.452.750.251.600.000.00 %00- %1815015:29:51
5.500. %084- %0444-
6.500. %0136- %0125-
7.500. %0195- %0156-
8.500. %00- %011-
9.500. %00- %00-


StrikeBid PriceAsk PriceLast PriceMidpointChangeChange %VolumeOPEN INTLast Trade %00-
1.500. %00- %00-
2.500. %00- %00-
3.500. %00- %00-
4.500. %02- %083-
5.500.052.300.301.1750.000.00 %052-
6.000.452.600.451.5250.000.00 %03-
6.500.953.300.002.1250.000.00 %00-
7.001.453.802.452.6250.000.00 %00-
7.501.954.300.003.1250.000.00 %00-
8.002.454.500.003.4750.000.00 %00-
8.502.955.300.004.1250.000.00 %00-
9.003.405.800.004.600.000.00 %00-
9.503.906.300. %00-
10.004.406.604.005.500.000.00 %00-

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
AIMDAinos Inc
$ 1.65
AADIAadi Bioscience Inc
$ 2.46
INDPIndaptus Therapeutics Inc
$ 2.40
GWAVGreenwave Technology Solutions Inc
$ 0.85
RELIReliance Global Group Inc
$ 0.58
BIVIBioVie Inc
$ 1.64
HCTIHealthcare Triangle Inc
$ 1.75
COCHEnvoy Medical Inc
$ 5.67
ASCAUA SPAC I Acquisition Corporation
$ 9.00
STCNSteel Connect Inc
$ 8.17
JAGXJaguar Health Inc
$ 0.0956
BIOLBiolase Inc
$ 0.1479
LYFTLyft Inc
$ 16.30
CELHCelsius Holdings Inc
$ 79.47
AIMDAinos Inc
$ 1.65

AVXL Discussion

View Posts
plexrec plexrec 1 minute ago
WilliamM--" I am sure that Missling won't fail to highlight this at the TD Cowen presentation on Monday."--great post--you nailed it! Looking for a job ??? Anavex could sure use you in their "Marketing Dept"
mrplmer mrplmer 15 minutes ago
WTF does he do all day? Looking at the presentation again it screams that this science need to be in the hands of a capable well funded BP
sumbuysumsell sumbuysumsell 15 minutes ago
So you're just here to bitch and claim no other ulterior agenda. Horseshat!
Awe. You sound upset. Does this mean we aren't going fishing next week? Would it help if I sent flowers?

Maybe someone could show you how to use the ignore feature and you could miss out on my nonsense since it doesn't fit with your things are good here and always have been and always will be indoctrination?

Maybe you bought Anavex because it was going to be an easy way to riches beyond your beliefs?

👍️ 1
WilliamMunny WilliamMunny 43 minutes ago
Yes, Besao, I saw part of Cramer's pitch on Lilly, and he attributed part of the recent strong movement in LLY to the anticipation of FDA approval for its new Alzheimer's drug, donanedab. I believe the company suggested that approved was expected in the next week or two. Like the Biogen/Eisai drug, lecanemab (LEQEMBI), as well as its now defunct predecessor, aducanemab (ADUHELM), donanemab is a monoclonal antibody (mAb) treatment that reduces the quantity of amyloid plaque in the brain and therefore hopefully retards the development of Alzheimer's. After decades of work in pursuit of that theory, the results from the mAb's have been disappointing to put it mildly. Donanemab might be somewhat better than LEQEMBI, but it certainly seems a huge stretch to call it a game changer. Like the others it requires infusions at a medical facility. The side effects can be quite serious, particularly cerebral edema potentially leading to life threatening brain bleeds. The latter possibility requires patients to receive regular brain scans. In addition, like its mAb predecessors, it accelerates brain shrinkage. Also a significant number of patients in the trials apparently dropped out because of nausea.

If you indeed read this board regularly, you know that blarcamesine, Anavex' current entry in the Alzheimer's field, does not have the serious safety issues common to the mAb's. There is no cerebral edema and therefore no need for ongoing brain scans. As I recall, there was no issue with nausea, as seemed to plague the donanemab trials. Some patients reported mild to moderate dizziness, and the company now recommending an evening dosing protocol. As you mentioned, it is a small molecule oral drug, in contrast to the mAb infusions (which may evolve into injections). As to efficacy, I would refer you to page 19 of the new (2024) Anavex Corporate Presentation on the company website. No longer does Anavex need to compare itself to ADUHELM, so now we see a chart of ADAS-COG showing that blarcamesine slows the cognitive decline vs. placebo by 28% over 48 weeks. That is a faster and stronger response than donanemab, which slows the cognitive decline vs. placebo by 19% over 76 weeks, as noted in the sidebar. I am sure that Missling won't fail to highlight this at the TD Cowen presentation on Monday.

So, of the two which is more likely to be the game changer? The stock price of AVXL should take care of itself after an MAA is filed and accepted at the EMA and and/or after the peer reviewed article is published.
🎯 1 👍️ 8
sage4 sage4 49 minutes ago
15 minutes are up, too late.
I'll need Anavex2-73 sooner or later. 😁
BIOChecker4 BIOChecker4 51 minutes ago
Georgejjl tends to post things without actually reading them, which makes him look silly.

You are correct, the 2024 corporate presentation says nothing about the EMA. Not even on slide 8, which lists “near term” catalysts. You would think that the MAA filing would at least rate inclusion on Slide 8.

As I said yesterday, at the conference Missling will race through the same 33 densely packed slides that no human could possibly follow (much less see on a smaller screen) or remember what they saw if they did.

What I’d like to know is what does that outside IR guy, Barwicki, actually do to justify his monthly retainer. In my experience, Anavex has the absolute worst communications of any company I’ve ever followed.

Every time Missling is going to present at an investor conference, the WGTers imagine (or predict) that huge news will be announced, and every time, without fail, they are disappointed and/or more confused than ever.

Does Missling do this on purpose, or does he just not understand that for investors less is actually more? Who knows.🤷‍♂️

DOG bless,
👍️ 1 👺 1 💩 2 💯 1 🤡 1
Investor2014 Investor2014 51 minutes ago
No substance differences compared to the Jan JPM presentation.

👺 1 💩 3 🤡 3
mrplmer mrplmer 53 minutes ago
A 237 ?
powerwalker powerwalker 53 minutes ago
It's a 'mab like Biosh**t's are ... dona*mab, I think is its name.

bas, you have #42!!
👍️ 2 🤣 1
sage4 sage4 59 minutes ago
You will get used to it very quick. Using ihub app is very convenient giving your index finger a break. And faster browsing though it lacks certain functions like editing your message.
I like the ihub app on my phone more than on the tablet.
Investorshub certainly needs to promote them more.
georgejjl georgejjl 1 hour ago
February 2024 corporate presentation


Good luck and GOD bless,
👍️ 1
georgejjl georgejjl 1 hour ago
Should you by AVXL stock shares before the GREAT NEWS or should you wait and buy after the GREAT NEWS

Good luck and GOD bless,
⛽️ 2
georgejjl georgejjl 1 hour ago

Good luck and GOD bless,
🤪 1
sage4 sage4 1 hour ago
Everyone is going to take the drug anyway because there’s nothing else out there.

So true except we now see many small bio companies with A/D drugs; one among them right behind us. It's been a long way since............... We heard that long long time ago "A237 is safe, has good efficacy and the bar is low". You shared your conversation with Dr. Missling after a CC many years ago if I remember correct. And lots of discussion on precision medicine which kind of had faded away till recent comeback.

Lately I've seen many Bio companies lost their value more than 66% for a mishap and they recovered back just in several months. Hope that's the case for Anavex in a couple of days or weeks. Or even months!
williamssc williamssc 1 hour ago
You just pumped Lilly bashed AVXL and then thanked us for it. Nice going.
👍️ 2 🤣 1
123tom 123tom 1 hour ago
@nidan... a good jump to start the day, climbed back to retest 5.40 but immediately sold down, and back down to test 5.20 support. Finishing the week, resting in neutral. Not much else to say, for the week. Weeks go by this way, sliding along. Waiting for news. February ended with a yearly Low at 4.80, and a small bounce to try and recover... ongoing ... needs to climb some more if we are to see the downwave pattern stop bleeding and turn around. First major recovery target in my view is 5.80 area. Not there yet. Critical support at 5.00 area must hold to keep the recovery momentum. The pattern will need to develop with higher highs and higher lows. Basic patterns to watch. 1 dollar trade wave targets at a time. Upward is looking at the 5.80 .... Downward is looking at 4.40. In the middle is the critical battle zone 5.10 to 5.30, where price sits now, ... waiting. 🤔 🫣
Investor2014 Investor2014 1 hour ago

Pathetic only up to 2022, everything Anavex since has just stood still!

Except for the share price of course.
👺 1 💩 2 🤡 1
Joseph_K Joseph_K 2 hours ago
Sage4, I hadn't known there was an app for iHub. Thanks. Loaded it on my Android tablet. So far I like it less than the browser interface, but I've been on it just a few minutes.
Steady_T Steady_T 2 hours ago
I would hope that sections of the MAA/NDA were already written.
Given the ongoing talks with the EMA CHMP I would guess that the actual trial data section is waiting on the outcome of those talks.
🎯 2 👍️ 2
BesaoT35 BesaoT35 2 hours ago
Jim Cramer on CNBC today around 9:30 ET discussed in some detail that Lilly has a new drug for Alzheimer’s that he thinks could receive FDA approval by the end of March 2024. He thinks that it is going to be a game changer for Alzheimer’s. I do read this AVXL board fairly regularly. I have not seen the Lilly drug discussed here or maybe I missed it.

Can anyone with knowledge about the field of Alzheimer’s treatment elaborate on this Lilly product. Could the AVXL drugs be used in combination with the Lilly drug? What is the name of the Lilly drug? What is the mechanism of action? Is it a small molecule oral drug that is simple to administer like the AVXL products?

The Lilly stock price is doing very well. They already have a blockbuster success with their GLP-1 agonist drugs for diabetes and for obesity. The AVXL stock price in stark contrast does not reflect much investor optimism. The phase 2b-3 for Alzheimer’s was declared to meet all end points in December of 2022 but that seems to be not believed to be true by Wall Street or by scientists in Neurology except for a few distinguished researchers. The peer reviewed article in a reputable journal could change things for us as would regulatory approval. Has Cramer ever mentioned AVXL?

🤡 2 🦨 1
Jonjones325 Jonjones325 2 hours ago
I hope Missling wasn’t penny wise and pound foolish when hiring a medical writing team to complete the MAA.

Some things you need to pay for to be done right and fast.
👍️ 1
georgejjl georgejjl 2 hours ago
AVXL $5.28 at the close of trading
Volume: 978,004
meds4life meds4life 2 hours ago
This presentation ..nothing about EMA submission ??
Jonjones325 Jonjones325 3 hours ago
Any thoughts as to whether or not our PDD data can be used as supplemental support in our MAA?

It’s odd that we didn’t pursue a P3 for PDD sooner as we had pretty robust data from our P2. And like others have pointed out, we never received guidance on that end on how to proceed. I mean it wasn’t made public. However I’m sure guidance was given.

So that program gets halted and we gleaned as much info as possible from it including the genetic mapping. All good while we wait for our Alz data. I guess now we plan a “real” PDD P3 with all that we learned.

Hope to see some “real precision medicine” plans in our design as we have spent so much time analyzing. Or do we just get a standard trial?

No point in getting all this data if it’s not put to good use. Yeah, we can tell you that possibly you may get a better effect based on your profile but does that really make a difference? Everyone is going to take the drug anyway because there’s nothing else out there.

It seems like 2-73 works pretty broadly so parsing out the differences in sub groups may not make much of a difference anyway in our success/failure/approval decision.

So we learn and learn and waste more time to end up with the same result and same customer base.

Maybe I just can’t see the forest.
georgejjl georgejjl 3 hours ago
Australia led the world charge of the Anavex2-73 Rett study

As most would know, Australia led the world charge of the Anavex2-73 Rett study here are some accounts of lived experiences from Patient stories currently on compassionate use of drug in Australia.

Good luck and GOD bless,
👍️ 1
Steady_T Steady_T 3 hours ago
The fact that Ern lives in Australia might make that a bit more difficult.

And ERN's current status is not particularly relevant at this point. Without knowing his complete medical history his current status would be less informative than you might think with one exception.
powerwalker powerwalker 3 hours ago
Need to add as manufacturing appears set:

Pantheon is part of Thermo Fisher Scientific, a very good group to be a part. The USA and Americas is covered.

Syntegon's headquarters are in Waiblingen (Germany). The largest location of the Syntegon Group is Crailsheim (Germany). Europe is covered.
🎯 2 👍️ 5 👎️ 1 💩 1
windsurfar51 windsurfar51 3 hours ago
Hi Bas. Just checking back in. So cool to see that I made the list!! Anyway, for what it's worth (anyone remember the Buffalo Springfield song?) the original patent appears to have been acquired January 31, 2007 (reading some old 10Ks). I know AVXL has other patents for related compounds and processes, but the company is not very transparent in that regard. I'll leave the board alone now. Oh, and GOD BLESS.
👺 1 💩 1 🤡 2
georgejjl georgejjl 3 hours ago
• >91% of patients completing the EXCELLENCE trial continued into a 48-week open-label extension study (OLE)

• To date, of the pediatric patients who completed the OLE, 93% have joined the Compassionate Use Program

• Compassionate Use level for adult patients from AVATAR trial after 48-week OLE is >96%

• As of today, some patients with Rett syndrome have been on blarcamesine-treatment for >4 years, combined OLE and Compassionate Use Program

Good luck and GOD bless,
🍼 2 🏧 1 👍️ 7 👏 5
georgejjl georgejjl 4 hours ago
Latest corporate presentation

Good luck and GOD bless,
🎯 1 👍️ 2 👎️ 2 💩 2
georgejjl georgejjl 4 hours ago
After 1:30 PM Monday potential catalyst

44th Annual TD Cowen Health Care Conference, March 4-6, 2024. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled at 1:30 PM (ET) on Monday, March 4th, 2024, at the Boston Marriott Copley Place in Boston, MA.

Good luck and GOD bless,
🎯 1 👍️ 1 👎️ 2 💩 2
nidan7500 nidan7500 4 hours ago
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
Anavex Life Sciences Corp.

PR Mon, Feb 26, 2024, 7:30

Anavex Life Sciences Corp.Anavex Life Sciences Corp.
Anavex Life Sciences Corp.
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the 44th Annual TD Cowen Health Care Conference, March 4-6, 2024. Christopher U Missling, PhD, President & Chief Executive Officer will present the Company in a session scheduled at 1:30 PM (ET) on Monday, March 4th, 2024, at the Boston Marriott Copley Place in Boston, MA.

I expect something news worthy to come from this conference EARLY next week in Boston. AVXL has several plates spinning including a possible peer review Publication news release, Update on AVXL EU Med AD trials, Rett syndrome-refresher update, A 3-71 schizophrenia trials status update, and possible AVXL CNS linked Precision Med suite initiative.

IMO, the timing/location selection could not be better for our purposes.
👍️ 1
catdaddy catdaddy 4 hours ago
So you're just here to bitch and claim no other ulterior agenda. Horseshat!
🍿 1 🎯 2 👍️ 3
bas2020 bas2020 4 hours ago
The 41 FUDstooges of AVXL that no one takes seriously... 👺
BIOChecker4 (voted biggest 👺)
go avxl
LakeshoreLeo1935 (voted biggest 🤡)
Gary, I know you have a comparable list for the NWBO MB.
🎯 3 🏆️ 1 👍️ 5 💩 1 🤪 1
georgejjl georgejjl 4 hours ago
Expect AVXL to close near the high of the day with over one million shares purchased today.

Good luck and GOD bless,
👎️ 2 💤 1 💩 2
LakeshoreLeo1953 LakeshoreLeo1953 5 hours ago
Likewise NO social media presence of ERN.
Strange not to tout your "successes" or at least track them.
👺 1 💩 1 🤡 2
LakeshoreLeo1953 LakeshoreLeo1953 5 hours ago
I can neither confirm nor deny the current health of one Ern Heaven.
However, it seems if I were to repeatedly cite an aging local news production
of a "wonder" outcome of even one patient, I would be able to post
confirming evidence of at least his existence.
👺 1 💩 1 🤡 2
k9uwa k9uwa 5 hours ago
I couldn't find an Obit for Ern A year or so ago also tried to track down several of the other Super Responders. With 5 or 6 super responders out a the SMALL N number I think it was only 27 in the test... 5 or 6 is a larger percentage of those in the test. I did find some references to the lady who was a book writer she had published another book some time past the end of the test.

John k9uwa
🍼 1 🎯 1 🏧 1 👍️ 3
sumbuysumsell sumbuysumsell 5 hours ago
You won't answer, will you?

The question has been asked and answered several times and yet you ask again. What's your deal? SMH.

As informational.....
Censorship, the suppression of words, images, or ideas that are “offensive,” happens whenever some people succeed in imposing their personal political or moral values on others. Censorship can be carried out by the government as well as private pressure groups. Censorship by the government is unconstitutional.
🎯 2 🏆️ 1 👍️ 2 👺 1 💩 1 🤡 2
georgejjl georgejjl 5 hours ago
Dr. A. Barrie Pittock, Nobel prize winner, is a participant in the Phase 2b/3 Alzheimer's trial.

Good luck and GOD bless,
🏆️ 1 👍️ 1 👎️ 2 💤 1 💩 2
georgejjl georgejjl 5 hours ago
Dr. A. Barrie Pittock, Nobel prize winner, is a participant in the Phase 2b/3 Alzheimer's trial.

Good luck and GOD bless,
🏆️ 1 👍️ 1 👎️ 2 💩 2
shortridge3w shortridge3w 6 hours ago

Alzheimer's Might Not Actually Be a Brain Disease, Expert Reveals
👍️ 1
BIOChecker4 BIOChecker4 6 hours ago
Yes, exactly. Speaking for myself, I believe the science is interesting and has potential but I don’t have confidence in Missling’s leadership based on his poor track record. I believe we shareholders would be better served if Anavex hired a seasoned CEO with the right kind of experience, a track record of success, and credibility with the larger biotech investment community and pharma. Officers and directors have a fiduciary obligation to enhance shareholder value. Missling has failed that responsibility and so have the directors.

As shareholders, we’re entitled to have top-flight leadership working tirelessly and flawlessly on our behalf. Is that too much to ask?


DOG bless,
🎯 1 🐀 1 👍️ 1 👺 1 💩 3 🤡 1
catdaddy catdaddy 6 hours ago
So, I guess you and others are attempting to effect change with all your bitching, whining, and negativity in every post.
🍼 1 🏧 1 👍️ 5 👏 2
BIOChecker4 BIOChecker4 7 hours ago
Please show us where it says that to post on this message board you must be a member of the WGT cult.

People can own shares of a company and bitterly disagree with management’s strategies or policies. Likewise, you can be a citizen of a country and bitterly disagree with the government’s strategies or policies.

DOG bless,
🎯 3 🐀 1 👍️ 3 👺 1 💩 3 🤡 1
Anshu2 Anshu2 7 hours ago
FIRST Q is whether the EMA submission will indeed happen. I'm not very confident. My personal probability of an EMA submission happening (ever) is 50%. If it doesn't happen --- I can't imagine it happening anytime before 3-4Q 24. My pessimism is well founded.
👍️ 1 👺 1 💩 5 🤡 2 🦨 1 ☹️ 1
nidan7500 nidan7500 7 hours ago
so far so good...5.41
As of 11:19 AM EST. Market Open.
WE ARE SOOOO OVERDUE...pray for a solid performance based on RWE-RWD
👍️ 1
powerwalker powerwalker 7 hours ago
JJ, the NYC comment was made 7-8 years ago as answer to the question if Anavex had enough product for the P2a trial in Australia.

It also, given the financial statement released at that time, implied the cost of production of one pill was less than a buck, and possibly as low as sixty cents … back then.
👍️ 3 👎️ 1 💩 1
mrplmer mrplmer 7 hours ago
I doubt Missling announces 3rd party Review on Monday. But that would get us to $12. If Sababbagh announces🤡 something great that could get us to $18
👍️ 1
catdaddy catdaddy 7 hours ago
You won't answer, will you?
🎯 1 👍️ 2 👏 1

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 |